Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,599.96
(
0.26%
)
US TECH 100
29,662.40
(
0.44%
)
Dow Jones
51,078.88
(
0.09%
)
Brent Oil
95.10
(
4.09%
)
Bitcoin
71,039.12
(
-3.42%
)
News Focus
News Focus
Post# of 257676
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123046
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 238735

Friday, 04/01/2022 10:27:22 AM

Friday, April 01, 2022 10:27:22 AM

Post# of 257676
MRK—Vaxneuvance sBLA for pediatrics gets 3-month extension to 7/1/22:

https://finance.yahoo.com/news/merck-provides-fda-review-supplemental-104500754.html

Vaxneuvance is already FDA-approved for adults (#msg-164961310), but I don’t think Vaxneuvance will compete effectively with PFE’s Prevnar-20, which has broader coverage of pneumococcal serotypes and a simpler (one-shot) treatment course (#msg-166441188).

p.s. MRK pays PFE a royalty of 7.25% on worldwide Vaxneuvance sales during 2022-2026 and a 2.5% royalty during 2027-2035 (#msg-166075692).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up